Cosmetic cross-reference Noindex: medium evidence

Ceramide

CAS 13031-64-6

Ceramide (CAS 13031-64-6) is a Phase 2 pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Ceramide
CAS Number
13031-64-6
UNII
ZZK8X1CR0R
InChIKey
CRJGESKKUOMBCT-VQTJNVASSA-N
ChEMBL ID
CHEMBL155886
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural product
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 2
Mid-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL155886 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Ceramide used for in pharmaceutical contexts?

Ceramide (CAS 13031-64-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Ceramide?

No adverse-event association or SIDER side-effect rows are rendered for Ceramide in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Ceramide also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for N-ACETYL DIHYDROSPHINGOSINE with EU status "permitted".

What clinical phase is Ceramide in?

Ceramide is rendered with ChEMBL max phase 2.